Vertex Pharmaceuticals (VRTX) Competitors $511.74 +8.54 (+1.70%) Closing price 04:00 PM EasternExtended Trading$513.11 +1.37 (+0.27%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VRTX vs. AMGN, GILD, REGN, ALNY, BIIB, UTHR, BMRN, INCY, NBIX, and EXELShould you be buying Vertex Pharmaceuticals stock or one of its competitors? The main competitors of Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Neurocrine Biosciences (NBIX), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry. Vertex Pharmaceuticals vs. Amgen Gilead Sciences Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics BioMarin Pharmaceutical Incyte Neurocrine Biosciences Exelixis Vertex Pharmaceuticals (NASDAQ:VRTX) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, community ranking, valuation, media sentiment, institutional ownership, risk, earnings and dividends. Do analysts rate VRTX or AMGN? Vertex Pharmaceuticals presently has a consensus target price of $506.70, indicating a potential downside of 0.99%. Amgen has a consensus target price of $314.04, indicating a potential downside of 0.11%. Given Amgen's higher probable upside, analysts plainly believe Amgen is more favorable than Vertex Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vertex Pharmaceuticals 0 Sell rating(s) 10 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.65Amgen 2 Sell rating(s) 10 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.46 Which has more risk and volatility, VRTX or AMGN? Vertex Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Do insiders & institutionals have more ownership in VRTX or AMGN? 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in VRTX or AMGN? Vertex Pharmaceuticals received 51 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 75.04% of users gave Vertex Pharmaceuticals an outperform vote while only 71.87% of users gave Amgen an outperform vote. CompanyUnderperformOutperformVertex PharmaceuticalsOutperform Votes160275.04% Underperform Votes53324.96% AmgenOutperform Votes155171.87% Underperform Votes60728.13% Is VRTX or AMGN more profitable? Amgen has a net margin of 12.24% compared to Vertex Pharmaceuticals' net margin of -4.86%. Amgen's return on equity of 176.32% beat Vertex Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Vertex Pharmaceuticals-4.86% -2.02% -1.49% Amgen 12.24%176.32%11.71% Does the media prefer VRTX or AMGN? In the previous week, Amgen had 11 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 52 mentions for Amgen and 41 mentions for Vertex Pharmaceuticals. Amgen's average media sentiment score of 1.53 beat Vertex Pharmaceuticals' score of 1.38 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 36 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 51 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has preferable earnings & valuation, VRTX or AMGN? Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVertex Pharmaceuticals$11.02B11.92-$535.60M-$2.20-232.61Amgen$33.42B5.05$4.09B$7.5541.64 SummaryAmgen beats Vertex Pharmaceuticals on 12 of the 18 factors compared between the two stocks. Remove Ads Get Vertex Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRTX vs. The Competition Export to ExcelMetricVertex PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$131.41B$7.11B$5.74B$8.28BDividend YieldN/A2.71%4.55%4.02%P/E Ratio-232.617.3324.7019.36Price / Sales11.92239.35396.6193.26Price / CashN/A65.6738.1634.64Price / Book8.016.787.154.51Net Income-$535.60M$142.41M$3.20B$247.14M7 Day Performance-0.39%3.81%1.84%2.69%1 Month Performance6.25%3.21%5.79%-3.39%1 Year Performance23.12%-4.64%15.10%5.06% Vertex Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRTXVertex Pharmaceuticals3.8592 of 5 stars$511.74+1.7%$506.70-1.0%+21.1%$131.41B$11.02B-232.616,100Positive NewsAMGNAmgen4.103 of 5 stars$317.97+1.4%$314.04-1.2%+14.4%$170.80B$33.42B42.1128,000Positive NewsGILDGilead Sciences4.4163 of 5 stars$112.33+0.8%$104.52-7.0%+47.5%$139.81B$28.75B303.4118,000Positive NewsREGNRegeneron Pharmaceuticals4.8288 of 5 stars$675.73+1.3%$973.13+44.0%-31.9%$73.96B$14.20B17.6711,900Positive NewsALNYAlnylam Pharmaceuticals4.1085 of 5 stars$251.62+4.1%$304.26+20.9%+93.4%$32.56B$2.25B-115.912,230Analyst ForecastNews CoverageBIIBBiogen4.8496 of 5 stars$143.41+2.8%$213.33+48.8%-35.4%$21.00B$9.68B12.828,720News CoveragePositive NewsUTHRUnited Therapeutics4.4084 of 5 stars$321.45+4.6%$388.25+20.8%+31.6%$14.45B$2.88B14.13980Positive NewsBMRNBioMarin Pharmaceutical4.9844 of 5 stars$71.41+2.8%$94.00+31.6%-16.3%$13.63B$2.85B32.473,401Analyst RevisionINCYIncyte4.8117 of 5 stars$63.13-7.0%$75.25+19.2%+8.7%$12.23B$4.24B233.992,617Analyst ForecastHigh Trading VolumeNBIXNeurocrine Biosciences4.8921 of 5 stars$112.52+1.6%$165.24+46.9%-20.9%$11.22B$2.36B34.211,200Positive NewsEXELExelixis4.6748 of 5 stars$37.21+1.5%$37.59+1.0%+55.4%$10.41B$2.17B21.021,147Positive News Remove Ads Related Companies and Tools Related Companies Amgen Alternatives Gilead Sciences Alternatives Regeneron Pharmaceuticals Alternatives Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives BioMarin Pharmaceutical Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRTX) was last updated on 3/24/2025 by MarketBeat.com Staff From Our PartnersMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMusk’s real agenda in D.C. Companies connected to Elon’s new map of America are making major climbs in price. And on May 30, the next wav...Porter & Company | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Vertex Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VRTX Stock Free VRTX Stock Alerts